Kazia Therapeutics Limited logo

Kazia Therapeutics Limited

ASX:KZA.AX

Overview | Financials
Company Name Kazia Therapeutics Limited
Symbol KZA.AX
Currency AUD
Price 0.08
Market Cap 18,907,919
Dividend Yield 0%
52-week-range 0.051 - 0.24
Industry Biotechnology
Sector Healthcare
CEO Dr. John E. Friend II, M.D.
Website https://www.kaziatherapeutics.com

An error occurred while fetching data.

About Kazia Therapeutics Limited

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company

Related Stocks

Prescient Therapeutics Limited logo

Prescient Therapeutics Limited

PTX.AX

0.041 AUD

Cann Group Limited logo

Cann Group Limited

CAN.AX

0.038 AUD

Proteomics International Laboratories Limited logo

Proteomics International Laboratories Limited

PIQ.AX

0.6 AUD

Vita Life Sciences Limited logo

Vita Life Sciences Limited

VLS.AX

2.15 AUD

SDI Limited logo

SDI Limited

SDI.AX

0.98 AUD

SomnoMed Limited logo

SomnoMed Limited

SOM.AX

0.44 AUD

Financials

Numbers are in millions USD

Numbers are in millions USD